-

06:44:50 AM

LIVE Real Time CEMI Stock Market News

CEMI - Chembio Diagnostics Inc.

04/22/21 8:00 AM

Nasdaq : CEMI

Chembio Diagnostics to Report First Quarter 2021 Financial Results on May 6, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2021 after the close of trading on Thursday,

RHEA-AI

neutral

04/01/21 5:30 PM

Nasdaq : CEMI

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on

RHEA-AI

neutral

03/11/21 4:05 PM

Nasdaq : CEMI

Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2020. Recent Accomplishments & Highlights Achieved

RHEA-AI

positive

03/08/21 8:00 AM

Nasdaq : CEMI

Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company's Board of Directors, effective upon his election on March 4,

RHEA-AI

very positive

02/25/21 4:05 PM

Nasdaq : CEMI

Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2020 after the close of trading on

RHEA-AI

neutral

01/14/21 7:00 AM

Nasdaq : CEMI

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the CE mark for the DPP SARS-CoV-2

RHEA-AI

very positive

12/17/20 4:05 PM

Nasdaq : CEMI

Chembio Diagnostics Appoints David Acheson, M.D. to its Board of Directors

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Acheson, M.D. to the Company's Board of Directors. "We are pleased to welcome David to

RHEA-AI

very positive

12/02/20 1:22 PM

Nasdaq : CEMI

Chembio Diagnostics Awarded $12.7 Million by BARDA for Development of Rapid DPP Respiratory Antigen Panel and 510(k) Submission of the Rapid DPP SARS-CoV-2 Antigen Test System

Chembio Diagnostics, Inc. (Nasdaq: CEMI) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA), which is

RHEA-AI

neutral

11/13/20 4:40 PM

Nasdaq : CEMI

Chembio Diagnostics Receives ANVISA Approval for DPP SARS-CoV-2 Antigen Test System in Brazil

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced that its subsidiary Chembio Diagnostics Brazil Ltda. has received regulatory approval from Agencia Nacional de

RHEA-AI

very positive

11/05/20 4:05 PM

Nasdaq : CEMI

Chembio Diagnostics Reports Third Quarter 2020 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended September 30, 2020. Recent Accomplishments & Highlights Achieved total

RHEA-AI

positive